Pfizer 2014 Annual Report Download - page 7

Download and view the complete annual report

Please find page 7 of the 2014 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 75

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75

PFIZER ANNUAL REVIEW 2014 www.pzer.com/annual 7
ANNUAL REVIEW 2014
REDUCING THE RISK OF NVAF-RELATED STROKES
“With a population that is living longer, the
prevalence of nonvalvular atrial fibrillation is
increasing, but many patients are still not being
managed effectively with warfarin.”
CHRISTOPHER GRANGER, M.D.
PROFESSOR OF MEDICINE
DIRECTOR, CARDIAC CARE UNIT
DUKE UNIVERSITY MEDICAL CENTER
Eliquis (apixaban) is a novel oral anticoagulant (NOAC) jointly
developed by Pzer and Bristol-Myers Squibb (BMS). Eliquis was
approved in the United States and the European Union in 2012
to reduce the risk of stroke and blood clots in people who have
nonvalvular atrial brillation (NVAF), a type of irregular heartbeat, not
caused by a heart valve problem.
Although it was launched third in the NOAC class, Eliquis has gained
signicant momentum worldwide due to its differentiated efcacy and
safety prole versus warfarin.
Another key element of success for Eliquis has been the strong
partnership between BMS and Pzer from clinical development of
the asset to its commercialization. Due largely to this successful
partnership, Eliquis has recently become the number one NOAC
prescribed by cardiologists for new to brand patients in the United
States, Japan and several other major markets.
In 2014, the European Commission and the U.S. Food and Drug
Administration approved Eliquis for new indications in the EU and the
U.S. to treat blood clots in the veins of the legs (deep vein thrombosis)
or lungs (pulmonary embolism), and reduce the risk of them occurring
again. In the U.S., additional indications to reduce the risk of forming a
blood clot in the legs and lungs of patients who have undergone hip or
knee replacement surgery was also approved in 2014.
ABOUT ELIQUIS
Eliquis (apixaban) is an oral selective Factor Xa inhibitor. By inhibiting
Factor Xa, a key blood clotting protein, Eliquis decreases thrombin
generation and blood clot formation. Eliquis is approved for multiple
indications in the U.S. based on efcacy and safety data, including
results from seven Phase 3 clinical trials. Eliquis is indicated to reduce
the risk of stroke and systemic embolism in patients with nonvalvular
atrial brillation; for the prophylaxis of deep vein thrombosis (DVT),
which may lead to pulmonary embolism (PE), in patients who have
undergone hip or knee replacement surgery; for the treatment of DVT
and PE; and to reduce the risk of recurrent DVT and PE following
initial therapy.
Eliquis® is a registered trademark of Bristol-Meyers Squibb.
ELIQUIS® PROVIDING
AN ALTERNATIVE TO WARFARIN
DISCOVERIES FOR HEALTHIER LIVES
Homepage > Discoveries for Healthier Lives